{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:49:07Z","timestamp":1766173747106,"version":"3.48.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":316,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.101036","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:49:53Z","timestamp":1763538593000},"page":"101036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oxaliplatin and\/or gemcitabine vs. FOLFIRINOX in first-line Advanced pancreatic adenocarcinoma: Real-world efficacy and safety data of moroccan patients"],"prefix":"10.1016","volume":"45","author":[{"given":"Hassan Abdelilah","family":"Tafenzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef Ait","family":"Takniouine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Essadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2025.101036_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","article-title":"Addressing the challenges of pancreatic cancer: future directions for improving outcomes","volume":"15","author":"Hidalgo","year":"2015","journal-title":"Pancreatology"},{"issue":"11","key":"10.1016\/j.ctarc.2025.101036_bib0002","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101036_bib0003","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.ctarc.2025.101036_bib0004","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ctarc.2025.101036_bib0005","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression","volume":"29","author":"Crane","year":"2011","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101036_bib0006","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of Immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.ctarc.2025.101036_bib0007","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without Tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMa Oncol."},{"issue":"26","key":"10.1016\/j.ctarc.2025.101036_bib0008","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer Julie","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ctarc.2025.101036_bib0009","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of Pembrolizumab (MK-3475; Anti\u2013PD-1 Monoclonal Antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ctarc.2025.101036_bib0010","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. ImmunOther"},{"issue":"10","key":"10.1016\/j.ctarc.2025.101036_bib0011","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3390\/cancers14102429","article-title":"Immunotherapy in pancreatic cancer: why do we keep failing? A focus on tumor immune microenvironment, predictive biomarkers and treatment outcomes","volume":"14","author":"Di Federico","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101036_bib0012","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101036_bib0013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.101036_bib0014","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 Stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101036_bib0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.ctarc.2025.101036_bib0016","first-page":"677","article-title":"Hacking pancreatic cancer: present and future of personalized medicine","volume":"14","author":"Di Federico","year":"2021","journal-title":"Pharm. Basel Switz."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101036_bib0017","first-page":"542","article-title":"Immunonutrition and prehabilitation in pancreatic cancer surgery: a new concept in the era of ERAS\u00ae and neoadjuvant treatment","volume":"49","author":"De Luca","year":"2023","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br Assoc. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2025.101036_bib0018","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/biology13050352","article-title":"Associations between \u2018cancer risk\u2019, \u2018inflammation\u2019 and \u2018metabolic syndrome\u2019: a scoping review","volume":"13","author":"Vitale","year":"2024","journal-title":"Biology"},{"issue":"6","key":"10.1016\/j.ctarc.2025.101036_bib0019","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.101036_bib0020","first-page":"205","volume":"92","author":"Therasse","year":"2000"},{"key":"10.1016\/j.ctarc.2025.101036_bib0021","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). 2017."},{"issue":"3","key":"10.1016\/j.ctarc.2025.101036_bib0022","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother. Rep."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101036_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R Stat .Soc. B Stat Methodol."},{"issue":"260","key":"10.1016\/j.ctarc.2025.101036_bib0024","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ctarc.2025.101036_bib0025","series-title":"Goodness-of-Fit Tests and Model Validity","first-page":"3","article-title":"Karl Pearson and the Chi-Squared test","author":"Cox","year":"2002"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101036_bib0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/00031305.1948.10502003","article-title":"Questions and answers","volume":"2","author":"Mosteller","year":"1948","journal-title":"Am. Stat."},{"key":"10.1016\/j.ctarc.2025.101036_bib0027","unstructured":"Nonparametric Estimation from Incomplete Observations | SpringerLink [Internet] [cited 2024 May 13]. Available from: https:\/\/link.springer.com\/chapter\/10.1007\/978-1-4612-4380-9_25."},{"issue":"19","key":"10.1016\/j.ctarc.2025.101036_bib0028","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2025.101036_bib0029","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2025.101036_bib0030","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","article-title":"Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline","volume":"34","author":"Balaban","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101036_bib0031","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"10409","key":"10.1016\/j.ctarc.2025.101036_bib0032","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctarc.2025.101036_bib0033","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and Gemcitabine with Nab-Paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMa Netw. Open."},{"issue":"15","key":"10.1016\/j.ctarc.2025.101036_bib0034","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ctarc.2025.101036_bib0035","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of Gemcitabine versus Gemcitabine Plus Capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.101036_bib0036","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cancers11040484","article-title":"Comparative effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"11","author":"Pusceddu","year":"2019","journal-title":"Cancers"},{"volume":"8","year":"2023","author":"Reni","key":"10.1016\/j.ctarc.2025.101036_bib0037"},{"issue":"16","key":"10.1016\/j.ctarc.2025.101036_bib0038","doi-asserted-by":"crossref","first-page":"16997","DOI":"10.1002\/cam4.6334","article-title":"Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: a single-center retrospective analysis","volume":"12","author":"Schlick","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2025.101036_bib0039","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.annonc.2024.05.519","article-title":"378P First-line systemic treatment outcomes in a real-world advanced pancreatic cancer cohort","volume":"35","author":"Tafenzi","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.101036_bib0040","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300144","article-title":"Nab-Paclitaxel plus Gemcitabine and FOLFOX in metastatic pancreatic cancer","volume":"3","author":"Carrato","year":"2024","journal-title":"NEJM. Evid."},{"issue":"32","key":"10.1016\/j.ctarc.2025.101036_bib0041","doi-asserted-by":"crossref","first-page":"232","DOI":"10.14694\/EdBook_AM.2012.32.173","article-title":"A new direction for pancreatic cancer treatment: FOLFIRINOX in context","author":"Kindler","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"1","key":"10.1016\/j.ctarc.2025.101036_bib0042","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/OP.22.00328","article-title":"Pancreatic adenocarcinoma management","volume":"19","author":"Jiang","year":"2023","journal-title":"JCO Oncol Pr."},{"issue":"6","key":"10.1016\/j.ctarc.2025.101036_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16199","article-title":"Comparison of FOLFIRINOX vs Gemcitabine plus Nab-Paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma","volume":"5","author":"Klein-Brill","year":"2022","journal-title":"JAMa Netw. Open."},{"issue":"15","key":"10.1016\/j.ctarc.2025.101036_bib0044","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with Gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:45:55Z","timestamp":1766173555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":44,"alternative-id":["S2468294225001728"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101036","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxaliplatin and\/or gemcitabine vs. FOLFIRINOX in first-line Advanced pancreatic adenocarcinoma: Real-world efficacy and safety data of moroccan patients","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.101036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101036"}}